| Date | Title | Description |
| 13.09.2024 | Breaking Barriers: The Fight Against Lymphoma and Bladder Cancer | In the realm of cancer awareness, two significant events recently unfolded, shining a light on the emotional and physical battles faced by patients. On one hand, World Lymphoma Awareness Day (WLAD) took center stage, while on the other, a g... |
| 13.09.2024 | BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk | SINGAPORE, Sept. 13, 2024 /PRNewswire/ -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is proud to join the global community in raising awareness about lymphoma on World Lymphoma Awareness Day (WLAD). L... |
| 09.09.2024 | A. Menarini Diagnostics and Nucleix announce a strategic partnership for a non-invasive bladder cancer test in Europe | Under the commercial agreement, A. Menarini Diagnostics will assume exclusive marketing of the non-invasive Bladder EpiCheck® test in Europe in the months ahead, providing patients and clinicians with a urine test to detect and monitor recu... |
| 09.09.2024 | A. Menarini Diagnostics and Nucleix announce a strategic partnership for a non-invasive bladder cancer test in Europe | Under the commercial agreement, A. Menarini Diagnostics will assume exclusive marketing of the non-invasive Bladder EpiCheck® test in Europe in the months ahead, providing patients and clinicians with a urine test to detect and monitor recu... |
| 30.08.2024 | Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for amivantamab-vmjw to identify patients with inoperable or recurrent NSCLC harbouring EGF... | Guardant360® CDx is the first blood-based companion diagnostic to be approved in Japan for the detection of EGFR exon 20 insertion mutations
TOKYO, Aug. 30, 2024 /PRNewswire/ -- Guardant Health Japan Corp. (HQ: Minato-ku, Tokyo/ Representat... |
| 22.08.2024 | Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16 | SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 16.08.2024 | Imfinzi approved in US for resectable lung cancer | Imfinzi approved in US for resectable lung cancer
Fri, Aug 16, 2024 08:00 CET Report this content
16 August 2024
Imfinzi approved in the US for the treatment of resectable
non-small cell lung cancer before and after surgery
Based on AEGEAN ... |
| 08.08.2024 | Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant | Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant Sarclisa (isatuximab) in combination with standard-of-care lenalidomide, bo... |
| 26.07.2024 | ODAC reviewed Imfinzi in resectable lung cancer | ODAC reviewed Imfinzi in resectable lung cancer
Fri, Jul 26, 2024 08:00 CET Report this content
26 July 2024
FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial resu... |
| 25.06.2024 | Update on Imfinzi ADJUVANT BR.31 trial | Update on Imfinzi ADJUVANT BR.31 trial
Tue, Jun 25, 2024 08:05 CET Report this content
25 June 2024
Update on ADJUVANT BR.31 Phase III trial
of Imfinzi in non-small cell lung cancer
High-level results from the ADJUVANT BR.31 Phase III trial... |
| 17.06.2024 | Imfinzi approved in the US for endometrial cancer | Imfinzi approved in the US for endometrial cancer
Mon, Jun 17, 2024 08:00 CET Report this content
17 June 2024
Imfinzi plus chemotherapy approved in the US for
mismatch repair deficient advanced or recurrent endometrial cancer
Approval base... |
| 03.06.2024 | Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […] | ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients atteints d’un myélome multiple nouvellement diagnostiqué, non éligibles à une t... |
| 03.06.2024 | Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 | ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination with standard-of-care bortezomib, le... |
| 27.05.2024 | Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation... | La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation L’examen prioritaire accordé par la FDA est motivé par les résulta... |
| 27.05.2024 | Dato-DXd improved OS in nonsquamous lung cancer | Dato-DXd improved OS in nonsquamous lung cancer
Mon, May 27, 2024 08:00 CET Report this content
This announcement contains inside information
27 May 2024
Datopotamab deruxtecan showed clinically meaningful overall survival
improvement vs. c... |
| 27.05.2024 | Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma | Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa would be the first an... |
| 14.05.2024 | CLS launches its Focal Laser Ablation system for prostate cancer in France in collaboration with MTEC Company | CLS launches its Focal Laser Ablation system for prostate cancer in France in collaboration with MTEC Company
Tue, May 14, 2024 10:00 CET Report this content
Lund, Sweden, May 14, 2024 – Clinical Laserthermia Systems AB (publ) (“CLS” or “th... |
| 02.05.2024 | Calquence combination improved PFS in 1L MCL | Calquence combination improved PFS in 1L MCL
Thu, May 02, 2024 08:00 CET Report this content
02 May 2024
Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival... |
| 29.04.2024 | Truqap recommended for EU breast cancer approval | Truqap recommended for EU breast cancer approval
Mon, Apr 29, 2024 08:05 CET Report this content
29 April 2024
Truqap plusFaslodex recommended for approval in the EU by CHMP for
patients with advanced ER-positive breast cancer
Recommendatio... |
| 29.04.2024 | Henlius Trastuzumab Receives FDA Approval in the United States | SHANGHAI, April 29, 2024 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company's business partner, Accord BioPharma Inc. (the U.S. specialty division of Intas Pharmaceuticals, Ltd.), has received approval from ... |
| 05.04.2024 | Imfinzi improved OS & PFS in limited-stage SCLC | Imfinzi improved OS & PFS in limited-stage SCLC
Fri, Apr 05, 2024 08:00 CET Report this content
05 April 2024
Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung ... |
| 02.04.2024 | FDA accepts Dato-DXd BLA for breast cancer | FDA accepts Dato-DXd BLA for breast cancer
Tue, Apr 02, 2024 08:00 CET Report this content
2 April 2024
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER... |
| 04.03.2024 | EMA validates Dato-DXd MAAs for NSQ NSCLC and BC | EMA validates Dato-DXd MAAs for NSQ NSCLC and BC
Mon, Mar 04, 2024 08:00 CET Report this content
4 March 2024
Two datopotamab deruxtecan applications validated in the EU for
patients with advanced nonsquamous non-small cell lung
cancer or H... |
| 19.02.2024 | Tagrisso improved PFS in Stage III lung cancer | Tagrisso improved PFS in Stage III lung cancer
Mon, Feb 19, 2024 08:00 CET Report this content
19 February 2024
Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA ... |
